Clinical Trial Update: Study to Evaluate GR1801's Efficacy and Safety [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating GR1801 for rabies post-exposure prophylaxis has completed, but no efficacy or safety results are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rabies

Drugs mentioned

• GR1801 (GR1801)

Snippet

Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Conditions: Rabies Post-exposure Prophylaxis | Phase 3 | Status: COMPLETED